---
document_datetime: 2025-12-02 04:57:15
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/medicines/human/EPAR/travatan.html
document_name: travatan.html
version: success
processing_time: 0.1185812
conversion_datetime: 2025-12-28 09:58:20.060387
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
# Travatan

[RSS](/en/individual-human-medicine.xml/65605)

##### Authorised

This medicine is authorised for use in the European Union

travoprost Medicine Human Authorised

Page contents

## Page contents

- [Overview](#overview)
- [Product information](#product-info)
- [Product details](#product-details)
- [Authorisation details](#authorisation-details)
- [Assessment history](#assessment-history)
- [News on Travatan](#news-on)
- [More information on Travatan](#related-medicines)
- [Topics](#topics)

- Application under evaluation
- CHMP opinion
- European Commission decision

## Overview

This is a summary of the European public assessment report (EPAR) for Travatan. It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for Travatan.

Expand section

Collapse section

## What is Travatan?

Travatan is a clear eye-drop solution that contains the active substance travoprost.

## What is Travatan used for?

Travatan is used to reduce intraocular pressure (pressure inside the eye). It is used in adults who have open-angle glaucoma (a disease where the pressure in the eye rises because fluid cannot drain out of the eye) and in adults with ocular hypertension (when the pressure in the eye is higher than normal). It can also be used in children from two months of age who have ocular hypertension or childhood glaucoma.

The medicine can only be obtained with a prescription.

## How is Travatan used?

The dose is one drop of Travatan in the affected eye(s) once a day, preferably in the evening.

If other eye drops are also being used, they should be given at least 5 minutes apart.

## How does Travatan work?

When intraocular pressure is raised, it causes damage to the retina (the light-sensitive membrane at the back of the eye) and to the optic nerve that sends signals from the eye to the brain. This can result in serious vision loss and even blindness. By lowering the pressure, Travatan reduces the risk of damage. The active substance in Travatan, travoprost, is a prostaglandin analogue (a man-made copy of a prostaglandin, one of a group of substances naturally found in the body). In the eye, prostaglandins increase the drainage of the watery fluid (aqueous humour) out of the eyeball. Travatan acts in the same way and increases the flow of fluid out of the eye. This helps to reduce the pressure inside the eye.

## How has Travatan been studied?

Travatan has been studied in 1,989 adult patients in three main studies, lasting between six and 12 months. All three studies compared travoprost with timolol, which is the standard treatment for glaucoma. One of the three trials also included a comparison with latanoprost (another prostaglandin analogue used for glaucoma). . A fourth study also compared the effectiveness of adding Travatan to treatment with timolol (427 patients, six-month duration). In addition, Travatan was compared with timolol in a fifth main study over 3 months, involving 152 children between 2 months and 18 years of age. The main measure of effectiveness in all studies was the reduction in intraocular pressure

## What benefit has Travatan shown during the studies?

Travatan was at least as effective as timolol and as effective as latanoprost in reducing intraocular pressure. The combined treatment with Travatan plus timolol produced an additional decrease of intraocular pressure in patients who were not controlled with timolol alone.

## What is the risk associated with Travatan?

The most common side effects when using Travatan (seen in more than 1 patient in 10) are ocular hyperaemia (increased blood supply to the eye, leading to eye irritation and redness) and iris hyperpigmentation (darkening of the colour of the iris). There may also be changes to the patient's eyelashes, including increased length, thickness, colour or number of lashes. Side effects reported in children are similar to those seen in adults. For the full list of all side effects and restrictions with Travatan, see the package leaflet.

## Why has Travatan been approved?

The CHMP decided that Travatan's benefits are greater than its risks and recommended that it be given marketing authorisation.

## Other information about Travatan

The European Commission granted a marketing authorisation valid throughout the European Union, for Travatan on 27 November 2001.

For more information about treatment with Travatan, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.

Travatan : EPAR - Summary for the public

English (EN) (73.26 KB - PDF)

**First published:** 10/07/2007

**Last updated:** 02/03/2015

[View](/en/documents/overview/travatan-epar-summary-public_en.pdf)

[Other languages (22)](#file-language-dropdown-685)

български (BG) (99.36 KB - PDF)

**First published:**

10/07/2007

**Last updated:**

02/03/2015

[View](/bg/documents/overview/travatan-epar-summary-public_bg.pdf)

español (ES) (73.11 KB - PDF)

**First published:**

10/07/2007

**Last updated:**

02/03/2015

[View](/es/documents/overview/travatan-epar-summary-public_es.pdf)

čeština (CS) (96.7 KB - PDF)

**First published:**

10/07/2007

**Last updated:**

02/03/2015

[View](/cs/documents/overview/travatan-epar-summary-public_cs.pdf)

dansk (DA) (72.72 KB - PDF)

**First published:**

10/07/2007

**Last updated:**

02/03/2015

[View](/da/documents/overview/travatan-epar-summary-public_da.pdf)

Deutsch (DE) (74.5 KB - PDF)

**First published:**

10/07/2007

**Last updated:**

02/03/2015

[View](/de/documents/overview/travatan-epar-summary-public_de.pdf)

eesti keel (ET) (72.28 KB - PDF)

**First published:**

10/07/2007

**Last updated:**

02/03/2015

[View](/et/documents/overview/travatan-epar-summary-public_et.pdf)

ελληνικά (EL) (99.58 KB - PDF)

**First published:**

10/07/2007

**Last updated:**

02/03/2015

[View](/el/documents/overview/travatan-epar-summary-public_el.pdf)

français (FR) (74.86 KB - PDF)

**First published:**

10/07/2007

**Last updated:**

02/03/2015

[View](/fr/documents/overview/travatan-epar-summary-public_fr.pdf)

hrvatski (HR) (90.1 KB - PDF)

**First published:**

10/07/2007

**Last updated:**

02/03/2015

[View](/hr/documents/overview/travatan-epar-summary-public_hr.pdf)

italiano (IT) (73.59 KB - PDF)

**First published:**

10/07/2007

**Last updated:**

02/03/2015

[View](/it/documents/overview/travatan-epar-summary-public_it.pdf)

latviešu valoda (LV) (93.7 KB - PDF)

**First published:**

10/07/2007

**Last updated:**

02/03/2015

[View](/lv/documents/overview/travatan-epar-summary-public_lv.pdf)

lietuvių kalba (LT) (94.33 KB - PDF)

**First published:**

10/07/2007

**Last updated:**

02/03/2015

[View](/lt/documents/overview/travatan-epar-summary-public_lt.pdf)

magyar (HU) (90.94 KB - PDF)

**First published:**

10/07/2007

**Last updated:**

02/03/2015

[View](/hu/documents/overview/travatan-epar-summary-public_hu.pdf)

Malti (MT) (97.56 KB - PDF)

**First published:**

10/07/2007

**Last updated:**

02/03/2015

[View](/mt/documents/overview/travatan-epar-summary-public_mt.pdf)

Nederlands (NL) (73.9 KB - PDF)

**First published:**

10/07/2007

**Last updated:**

02/03/2015

[View](/nl/documents/overview/travatan-epar-summary-public_nl.pdf)

polski (PL) (99.18 KB - PDF)

**First published:**

10/07/2007

**Last updated:**

02/03/2015

[View](/pl/documents/overview/travatan-epar-summary-public_pl.pdf)

português (PT) (72.8 KB - PDF)

**First published:**

10/07/2007

**Last updated:**

02/03/2015

[View](/pt/documents/overview/travatan-epar-summary-public_pt.pdf)

română (RO) (93.12 KB - PDF)

**First published:**

10/07/2007

**Last updated:**

02/03/2015

[View](/ro/documents/overview/travatan-epar-summary-public_ro.pdf)

slovenčina (SK) (96.53 KB - PDF)

**First published:**

10/07/2007

**Last updated:**

02/03/2015

[View](/sk/documents/overview/travatan-epar-summary-public_sk.pdf)

slovenščina (SL) (109.38 KB - PDF)

**First published:**

10/07/2007

**Last updated:**

02/03/2015

[View](/sl/documents/overview/travatan-epar-summary-public_sl.pdf)

Suomi (FI) (72.03 KB - PDF)

**First published:**

10/07/2007

**Last updated:**

02/03/2015

[View](/fi/documents/overview/travatan-epar-summary-public_fi.pdf)

svenska (SV) (72.74 KB - PDF)

**First published:**

10/07/2007

**Last updated:**

02/03/2015

[View](/sv/documents/overview/travatan-epar-summary-public_sv.pdf)

Travatan : EPAR - Risk-management-plan summary

English (EN) (72.26 KB - PDF)

**First published:** 14/12/2020

[View](/en/documents/rmp-summary/travatan-epar-risk-management-plan-summary_en.pdf)

## Product information

Travatan : EPAR - Product Information

English (EN) (298.08 KB - PDF)

**First published:** 03/02/2009

**Last updated:** 18/12/2024

[View](/en/documents/product-information/travatan-epar-product-information_en.pdf)

[Other languages (24)](#file-language-dropdown-836)

български (BG) (404.61 KB - PDF)

**First published:**

03/02/2009

**Last updated:**

18/12/2024

[View](/bg/documents/product-information/travatan-epar-product-information_bg.pdf)

español (ES) (303.35 KB - PDF)

**First published:**

03/02/2009

**Last updated:**

18/12/2024

[View](/es/documents/product-information/travatan-epar-product-information_es.pdf)

čeština (CS) (375.82 KB - PDF)

**First published:**

03/02/2009

**Last updated:**

18/12/2024

[View](/cs/documents/product-information/travatan-epar-product-information_cs.pdf)

dansk (DA) (304.02 KB - PDF)

**First published:**

03/02/2009

**Last updated:**

18/12/2024

[View](/da/documents/product-information/travatan-epar-product-information_da.pdf)

Deutsch (DE) (296.64 KB - PDF)

**First published:**

03/02/2009

**Last updated:**

18/12/2024

[View](/de/documents/product-information/travatan-epar-product-information_de.pdf)

eesti keel (ET) (306.46 KB - PDF)

**First published:**

03/02/2009

**Last updated:**

18/12/2024

[View](/et/documents/product-information/travatan-epar-product-information_et.pdf)

ελληνικά (EL) (406.07 KB - PDF)

**First published:**

03/02/2009

**Last updated:**

18/12/2024

[View](/el/documents/product-information/travatan-epar-product-information_el.pdf)

français (FR) (317.24 KB - PDF)

**First published:**

03/02/2009

**Last updated:**

18/12/2024

[View](/fr/documents/product-information/travatan-epar-product-information_fr.pdf)

hrvatski (HR) (375.56 KB - PDF)

**First published:**

03/02/2009

**Last updated:**

18/12/2024

[View](/hr/documents/product-information/travatan-epar-product-information_hr.pdf)

íslenska (IS) (301.94 KB - PDF)

**First published:**

03/02/2009

**Last updated:**

18/12/2024

[View](/is/documents/product-information/travatan-epar-product-information_is.pdf)

italiano (IT) (339.13 KB - PDF)

**First published:**

03/02/2009

**Last updated:**

18/12/2024

[View](/it/documents/product-information/travatan-epar-product-information_it.pdf)

latviešu valoda (LV) (389.82 KB - PDF)

**First published:**

03/02/2009

**Last updated:**

18/12/2024

[View](/lv/documents/product-information/travatan-epar-product-information_lv.pdf)

lietuvių kalba (LT) (404.85 KB - PDF)

**First published:**

03/02/2009

**Last updated:**

18/12/2024

[View](/lt/documents/product-information/travatan-epar-product-information_lt.pdf)

magyar (HU) (353.11 KB - PDF)

**First published:**

03/02/2009

**Last updated:**

18/12/2024

[View](/hu/documents/product-information/travatan-epar-product-information_hu.pdf)

Malti (MT) (443.83 KB - PDF)

**First published:**

03/02/2009

**Last updated:**

18/12/2024

[View](/mt/documents/product-information/travatan-epar-product-information_mt.pdf)

Nederlands (NL) (307.26 KB - PDF)

**First published:**

03/02/2009

**Last updated:**

18/12/2024

[View](/nl/documents/product-information/travatan-epar-product-information_nl.pdf)

norsk (NO) (307.17 KB - PDF)

**First published:**

03/02/2009

**Last updated:**

18/12/2024

[View](/no/documents/product-information/travatan-epar-product-information_no.pdf)

polski (PL) (387.91 KB - PDF)

**First published:**

03/02/2009

**Last updated:**

18/12/2024

[View](/pl/documents/product-information/travatan-epar-product-information_pl.pdf)

português (PT) (305.02 KB - PDF)

**First published:**

03/02/2009

**Last updated:**

18/12/2024

[View](/pt/documents/product-information/travatan-epar-product-information_pt.pdf)

română (RO) (391.14 KB - PDF)

**First published:**

03/02/2009

**Last updated:**

18/12/2024

[View](/ro/documents/product-information/travatan-epar-product-information_ro.pdf)

slovenčina (SK) (395.63 KB - PDF)

**First published:**

03/02/2009

**Last updated:**

18/12/2024

[View](/sk/documents/product-information/travatan-epar-product-information_sk.pdf)

slovenščina (SL) (369.84 KB - PDF)

**First published:**

03/02/2009

**Last updated:**

18/12/2024

[View](/sl/documents/product-information/travatan-epar-product-information_sl.pdf)

Suomi (FI) (292.71 KB - PDF)

**First published:**

03/02/2009

**Last updated:**

18/12/2024

[View](/fi/documents/product-information/travatan-epar-product-information_fi.pdf)

svenska (SV) (302.25 KB - PDF)

**First published:**

03/02/2009

**Last updated:**

18/12/2024

[View](/sv/documents/product-information/travatan-epar-product-information_sv.pdf)

**Latest procedure affecting product information:** IAIN/0072/G 16/12/2024

icon globe

<!-- image -->

This medicine's product information is available in all **official EU languages** . Select 'available languages' to access the language you need.

Product information documents contain:

- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).

Travatan : EPAR - All Authorised presentations

English (EN) (57.8 KB - PDF)

**First published:** 26/10/2006

**Last updated:** 27/05/2015

[View](/en/documents/all-authorised-presentations/travatan-epar-all-authorised-presentations_en.pdf)

[Other languages (24)](#file-language-dropdown-314)

български (BG) (63.57 KB - PDF)

**First published:**

26/10/2006

**Last updated:**

27/05/2015

[View](/bg/documents/all-authorised-presentations/travatan-epar-all-authorised-presentations_bg.pdf)

español (ES) (56.51 KB - PDF)

**First published:**

26/10/2006

**Last updated:**

27/05/2015

[View](/es/documents/all-authorised-presentations/travatan-epar-all-authorised-presentations_es.pdf)

čeština (CS) (60.66 KB - PDF)

**First published:**

26/10/2006

**Last updated:**

27/05/2015

[View](/cs/documents/all-authorised-presentations/travatan-epar-all-authorised-presentations_cs.pdf)

dansk (DA) (60.78 KB - PDF)

**First published:**

26/10/2006

**Last updated:**

27/05/2015

[View](/da/documents/all-authorised-presentations/travatan-epar-all-authorised-presentations_da.pdf)

Deutsch (DE) (58.41 KB - PDF)

**First published:**

26/10/2006

**Last updated:**

27/05/2015

[View](/de/documents/all-authorised-presentations/travatan-epar-all-authorised-presentations_de.pdf)

eesti keel (ET) (58.74 KB - PDF)

**First published:**

26/10/2006

**Last updated:**

27/05/2015

[View](/et/documents/all-authorised-presentations/travatan-epar-all-authorised-presentations_et.pdf)

ελληνικά (EL) (63.27 KB - PDF)

**First published:**

26/10/2006

**Last updated:**

27/05/2015

[View](/el/documents/all-authorised-presentations/travatan-epar-all-authorised-presentations_el.pdf)

français (FR) (60.17 KB - PDF)

**First published:**

26/10/2006

**Last updated:**

27/05/2015

[View](/fr/documents/all-authorised-presentations/travatan-epar-all-authorised-presentations_fr.pdf)

hrvatski (HR) (59.87 KB - PDF)

**First published:**

26/10/2006

**Last updated:**

27/05/2015

[View](/hr/documents/all-authorised-presentations/travatan-epar-all-authorised-presentations_hr.pdf)

íslenska (IS) (61.79 KB - PDF)

**First published:**

26/10/2006

**Last updated:**

27/05/2015

[View](/is/documents/all-authorised-presentations/travatan-epar-all-authorised-presentations_is.pdf)

italiano (IT) (56.88 KB - PDF)

**First published:**

26/10/2006

**Last updated:**

27/05/2015

[View](/it/documents/all-authorised-presentations/travatan-epar-all-authorised-presentations_it.pdf)

latviešu valoda (LV) (62.03 KB - PDF)

**First published:**

26/10/2006

**Last updated:**

27/05/2015

[View](/lv/documents/all-authorised-presentations/travatan-epar-all-authorised-presentations_lv.pdf)

lietuvių kalba (LT) (61.15 KB - PDF)

**First published:**

26/10/2006

**Last updated:**

27/05/2015

[View](/lt/documents/all-authorised-presentations/travatan-epar-all-authorised-presentations_lt.pdf)

magyar (HU) (57.78 KB - PDF)

**First published:**

26/10/2006

**Last updated:**

27/05/2015

[View](/hu/documents/all-authorised-presentations/travatan-epar-all-authorised-presentations_hu.pdf)

Malti (MT) (63.26 KB - PDF)

**First published:**

26/10/2006

**Last updated:**

27/05/2015

[View](/mt/documents/all-authorised-presentations/travatan-epar-all-authorised-presentations_mt.pdf)

Nederlands (NL) (77.97 KB - PDF)

**First published:**

26/10/2006

**Last updated:**

27/05/2015

[View](/nl/documents/all-authorised-presentations/travatan-epar-all-authorised-presentations_nl.pdf)

norsk (NO) (60.4 KB - PDF)

**First published:**

26/10/2006

**Last updated:**

27/05/2015

[View](/no/documents/all-authorised-presentations/travatan-epar-all-authorised-presentations_no.pdf)

polski (PL) (62.23 KB - PDF)

**First published:**

26/10/2006

**Last updated:**

27/05/2015

[View](/pl/documents/all-authorised-presentations/travatan-epar-all-authorised-presentations_pl.pdf)

português (PT) (59.37 KB - PDF)

**First published:**

26/10/2006

**Last updated:**

27/05/2015

[View](/pt/documents/all-authorised-presentations/travatan-epar-all-authorised-presentations_pt.pdf)

română (RO) (61.66 KB - PDF)

**First published:**

26/10/2006

**Last updated:**

27/05/2015

[View](/ro/documents/all-authorised-presentations/travatan-epar-all-authorised-presentations_ro.pdf)

slovenčina (SK) (63.4 KB - PDF)

**First published:**

26/10/2006

**Last updated:**

27/05/2015

[View](/sk/documents/all-authorised-presentations/travatan-epar-all-authorised-presentations_sk.pdf)

slovenščina (SL) (59.6 KB - PDF)

**First published:**

26/10/2006

**Last updated:**

27/05/2015

[View](/sl/documents/all-authorised-presentations/travatan-epar-all-authorised-presentations_sl.pdf)

Suomi (FI) (58.66 KB - PDF)

**First published:**

26/10/2006

**Last updated:**

27/05/2015

[View](/fi/documents/all-authorised-presentations/travatan-epar-all-authorised-presentations_fi.pdf)

svenska (SV) (60.32 KB - PDF)

**First published:**

26/10/2006

**Last updated:**

27/05/2015

[View](/sv/documents/all-authorised-presentations/travatan-epar-all-authorised-presentations_sv.pdf)

## Product details

Name of medicine Travatan Active substance travoprost International non-proprietary name (INN) or common name travoprost Therapeutic area (MeSH)

- Glaucoma, Open-Angle
- Ocular Hypertension

Anatomical therapeutic chemical (ATC) code S01EE04

### Pharmacotherapeutic group

Ophthalmologicals

### Therapeutic indication

Decrease of elevated intraocular pressure in adult patients with ocular hypertension or open-angle glaucoma (see section 5.1).

Decrease of elevated intraocular pressure in paediatric patients aged 2 months to &lt; 18 years with ocular hypertension or paediatric glaucoma (see section 5.1).

## Authorisation details

EMA product number EMEA/H/C/000390 Marketing authorisation holder

Novartis Europharm Limited

Vista Building

Marketing authorisation issued 27/11/2001 Revision 31

## Assessment history

Expand section

Collapse section

## Changes since initial authorisation of medicine

Travatan : EPAR - Procedural steps taken and scientific information after authorisation

English (EN) (178.65 KB - PDF)

**First published:** 03/02/2009

**Last updated:** 18/12/2024

[View](/en/documents/procedural-steps-after/travatan-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf)

Travatan : EPAR - Paediatric investigation plan compliance statement

Reference Number: EMA/288751/2015

English (EN) (68.5 KB - PDF)

**First published:** 07/05/2015

**Last updated:** 07/05/2015

[View](/en/documents/pip-compliance/travatan-epar-paediatric-investigation-plan-compliance-statement_en.pdf)

Travatan-H-C-390-II-0046-G : EPAR - Assessment Report - Variation

Adopted

Reference Number: EMA/CHMP/673466/2014

English (EN) (1.24 MB - PDF)

**First published:** 02/03/2015

**Last updated:** 02/03/2015

[View](/en/documents/variation-report/travatan-h-c-390-ii-0046-g-epar-assessment-report-variation_en.pdf)

CHMP post-authorisation summary of positive opinion for Travatan

Reference Number: EMA/CHMP/697464/2014

English (EN) (74.29 KB - PDF)

**First published:** 21/11/2014

**Last updated:** 21/11/2014

[View](/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-travatan_en.pdf)

Travatan : EPAR - Steps taken after authorisation when a cutoff date has been used

English (EN) (21.46 KB - PDF)

**First published:** 26/10/2006

**Last updated:** 26/10/2006

[View](/en/documents/steps-after-cutoff/travatan-epar-steps-taken-after-authorisation-when-cutoff-date-has-been-used_en.pdf)

## Initial marketing authorisation documents

Travatan : EPAR - Scientific Discussion

English (EN) (434.03 KB - PDF)

**First published:** 26/10/2006

**Last updated:** 26/10/2006

[View](/en/documents/scientific-discussion/travatan-epar-scientific-discussion_en.pdf)

Travatan : EPAR - Procedural steps taken before authorisation

English (EN) (98.13 KB - PDF)

**First published:** 26/10/2006

**Last updated:** 26/10/2006

[View](/en/documents/procedural-steps/travatan-epar-procedural-steps-taken-authorisation_en.pdf)

#### News on Travatan

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 17-20 November 2014](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-17-20-november-2014) 21/11/2014

#### More information on Travatan

- [EMEA-001271-PIP01-12-M01 - paediatric investigation plan](/en/medicines/human/paediatric-investigation-plans/emea-001271-pip01-12-m01)

#### Topics

- [Medicines](https://www.ema.europa.eu/en/search?f%5B0%5D=ema_search_topics%3A61)

**This page was last updated on** 18/12/2024

## Share this page

[Back to top](#main-content)